Brokers Set Expectations for RVMD FY2026 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Brookline Capital Markets issued their FY2026 earnings per share (EPS) estimates for Revolution Medicines in a report released on Wednesday, November 4th. Brookline Capital Markets analyst L. Cann forecasts that the company will earn ($8.71) per share for the year. Brookline Capital Markets currently has a “Buy” rating and a $318.00 target price on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($7.68) per share. Brookline Capital Markets also issued estimates for Revolution Medicines’ Q4 2026 earnings at ($2.27) EPS, FY2027 earnings at ($5.10) EPS and FY2028 earnings at $0.73 EPS.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, topping the consensus estimate of ($2.35) by $0.45. The company had revenue of $197.56 million for the quarter, compared to analyst estimates of $25.58 million. During the same period in the prior year, the business earned ($1.61) earnings per share.

Other equities analysts also recently issued research reports about the stock. Bank of America cut their price objective on shares of Revolution Medicines from $265.00 to $264.00 and set a “buy” rating for the company in a research report on Friday, October 9th. Truist Financial reaffirmed a “buy” rating and issued a $261.00 target price (up from $241.00) on shares of Revolution Medicines in a report on Thursday, November 5th. Royal Bank Of Canada lifted their target price on shares of Revolution Medicines from $260.00 to $321.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Wedbush boosted their price target on shares of Revolution Medicines from $201.00 to $225.00 and gave the stock an “outperform” rating in a research note on Thursday, August 27th. Finally, Piper Sandler increased their price target on shares of Revolution Medicines from $210.00 to $222.00 and gave the stock an “overweight” rating in a report on Thursday, November 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Revolution Medicines has a consensus rating of “Moderate Buy” and a consensus target price of $263.15.

Revolution Medicines Price Performance

Shares of RVMD opened at $193.06 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 8.36 and a quick ratio of 8.34. The company’s fifty day moving average is $196.48 and its two-hundred day moving average is $158.35. Revolution Medicines has a 1 year low of $62.29 and a 1 year high of $224.31.

Institutional Investors Weigh In On Revolution Medicines

Several institutional investors have recently made changes to their positions in RVMD. Burkett Financial Services LLC acquired a new position in shares of Revolution Medicines during the 3rd quarter worth $27,000. Contravisory Investment Management Inc. purchased a new position in shares of Revolution Medicines in the 2nd quarter valued at about $32,000. Johnson Financial Group Inc. acquired a new stake in shares of Revolution Medicines in the second quarter valued at about $37,000. Silvant Capital Management LLC acquired a new stake in shares of Revolution Medicines in the second quarter valued at about $41,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Revolution Medicines in the second quarter valued at about $41,000. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, COO Margaret A. Horn sold 4,967 shares of the company’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $989,625.08. Following the transaction, the chief operating officer owned 149,680 shares of the company’s stock, valued at $29,822,243.20. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Elizabeth M. Anderson sold 10,143 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $193.04, for a total value of $1,958,004.72. Following the completion of the transaction, the director owned 4,333 shares of the company’s stock, valued at $836,442.32. The trade was a 70.07% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 290,991 shares of company stock worth $59,422,765. Corporate insiders own 7.60% of the company’s stock.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates across several periods, including projecting FY2027 EPS of $0.20 versus its prior estimate of a $6.86 loss. It maintained a Buy rating and a $350 price target. These forecasts imply a notably improved earnings outlook, although they are analyst projections, not company guidance. MarketBeat analyst estimates
• Positive Sentiment: A Zacks report cited a consensus price target implying 33.3% upside and said upward earnings-estimate revisions may be a near-term positive. It also cautioned that price targets alone have limited predictive value. Zacks analyst outlook
• Neutral Sentiment: A short-interest update described a significant increase but reported zero shares sold short and zero days to cover. Those figures conflict, so the update offers no clear signal about positioning.

Revolution Medicines Company Profile

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.